Editor Brian Harrod Provides Comprehensive up-to-date news coverage, with aggregated news from sources all over the world from the Roundup Newswires Network
The pro-Brexit promises were that Brexit would be so awesome because it would fund the tremendously popular single-payer National Healthcare program in Britain. But it's not like the pro-leavers put it on the side of a bus or anything.
The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased American Depositary Shares of Teva between February 10, 2015 and November 3, 2016 . The case, Galmi v. Teva Pharmaceutical Industries Limited et al , No.
If you're feeling bereft, take note: Bernie Sanders is still here loudly fighting the good fight, this week blasting the avarice of Big Pharma so persuasively he sent their stock prices plunging to a seven-month low. After battling Big Pharma for decades - pillorying the makers of the emergency allergy injection EpiPen for obscenely jacking up their prices, recently calling out another company's price hikes on leukemia drugs, and campaigning this fall to stop price-gouging by seen by many as Ground Zero for drug companies and their 1,266 D.C. lobbyists - Bernie isn't letting up.
Makers of insulin became the latest target for Senator Bernie Sanders, who has been going after pharmaceutical companies one by one over the issue of high U.S. drug prices. Shares of Eli Lilly & Co.
Shares of Eli Lilly were sliding in early-afternoon trading on Tuesday after Senator Bernie Sanders criticized the price increase of the company's Humalog insulin. Why has the price of Humalog insulin gone up 700% in 20 years? It's simple.
These bearish sentiments first started with Valeant Pharmaceuticals, then Gilead and Turing Pharmaceuticals, and are now adversely affecting ETFs that hold any of these or their peers/competitors. It is my contention that the market is accustomed to common arbitrage opportunities, and when an even-driven opportunity emerges masking itself as a headwind, investors flee.
The brokerage currently has a $27.00 price target on the medical device company's stock. Zacks Investment Research's target price would suggest a potential upside of 13.66% from the company's current price.
For months, my office has heard from families concerned about their ability to afford a device they desperately need in the event that a loved one suffers a sudden allergic reaction. Parents should not have to worry about whether they can afford an EpiPen for their children.
By deciding not to split in two after a lengthy evaluation, the New York-based drugmaker is keeping greater leverage with the health insurers and pharmacy benefit managers that have gained increasing power since it first considered a breakup years ago. Had it broken up, Pfizer would have turned into one company with older and generic products, and another with newer products.
Mylan NV CEO Heather Bresch faced tough questioning Wednesday from Republicans and Democrats in Congress probing price increases for the EpiPen allergy treatment.
Mylan CEO Heather Bresch takes her seat on Capitol Hill in Washington, Wednesday prior to testifying before the House Oversight Committee hearing on EpiPen price increases. Bresch defended the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers.
The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers. "Price and access exist in a balance, and we believe we have struck that balance," Heather Bresch says in prepared testimony released by the House Oversight and Government Reform Committee ahead of her Wednesday appearance before the panel.
In this file photo, a pharmacist holds a package of EpiPens epinephrine auto-injector, a Mylan product, in Sacramento Mylan CEO Heather Bresch is defending the cost for life-saving EpiPens and is offering no suggestion that there are plans to lower prices. Bresch's prepared testimony was released by the House Oversight and Government Reform Committee ahead of her Sept.
PATERSON, NJ [September 19, 2016] - St. Joseph's Healthcare System, New Jersey's premier Catholic healthcare system, launched a year-long series of 150th Anniversary celebrations on Thursday, September 8th with the unveiling of a historic marker to commemorate the humble beginnings of St. Joseph's Hospital. Paterson's first hospital, now known as St. Joseph's Regional Medical Center, a member of the Healthcare System, was established by the Sisters of Charity of Saint Elizabeth on September 8, 1867, in response to the industrialized City's dire need for carea body, mind and spirit.
EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. Mylan NL Chief Executive Officer Heather Bresch will appear at a Sept.
Sado-masochism has evidently become the fashion in the pharmaceutical industry. A case in point is Mylan's decision to raise the price of their EpiPen to $600.
Mylan NV's latest attempt to deflect criticism over the price of allergy shot EpiPen failed to get the drugmaker out of the sights of Congress. Last week, Chief Executive Officer Heather Bresch was quick to react to the mounting political scrutiny over EpiPen's price hike with measures to reduce patients' out-of-pocket costs for the shot's $600 brand-name version.
Give Hillary Clinton credit for calling out Mylan NV for price-gouging on its Epi-Pen emergency allergy shot. While a bipartisan group of U.S. Senators initially raised a ruckus over the drug's 400 percent cost increase, it was Clinton's voice that brought pressure to bear on the company to reduce prices.